1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Emerging Markets
3.7 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Non-Invasive Cancer Diagnostics Market, By Therapeutics
5.1 Introduction
5.2 Lung Cancer
5.3 Breast Cancer
5.4 Solid Tumors
5.5 Blood Cancer
5.6 Other Therapeutics
6 Global Non-Invasive Cancer Diagnostics Market, By Technology
6.1 Introduction
6.2 Clinical Chemistry
6.3 Spectroscopy
6.4 Immunoassay
6.5 Molecular Diagnostics
6.6 Other Technologies
7 Global Non-Invasive Cancer Diagnostics Market, End user
7.1 Introduction
7.2 Hospitals & Clinics
7.3 Ambulatory Care
7.4 Other End Users
8 Global Non-Invasive Cancer Diagnostics Market, By Geography
8.1 Introduction
8.2 North America
8.2.1 US
8.2.2 Canada
8.2.3 Mexico
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 Italy
8.3.4 France
8.3.5 Spain
8.3.6 Rest of Europe
8.4 Asia Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 New Zealand
8.4.6 South Korea
8.4.7 Rest of Asia Pacific
8.5 South America
8.5.1 Argentina
8.5.2 Brazil
8.5.3 Chile
8.5.4 Rest of South America
8.6 Middle East & Africa
8.6.1 Saudi Arabia
8.6.2 UAE
8.6.3 Qatar
8.6.4 South Africa
8.6.5 Rest of Middle East & Africa
9 Key Developments
9.1 Agreements, Partnerships, Collaborations and Joint Ventures
9.2 Acquisitions & Mergers
9.3 New Product Launch
9.4 Expansions
9.5 Other Key Strategies
10 Company Profiling
10.1 Gen-Probe Inc
10.2 Digene Corporation
10.3 Quest Diagnostics Inc
10.4 Genetics Inc
10.5 BIOVIEW Inc
10.6 AVIVA Biosciences Corporation
10.7 Dr Lal PathLabs Ltd.
10.8 Laboratory Corporation of America Holdings (LabCorp)
10.9 A&G Pharmaceutical
10.10 Roche Holding AG
10.11 Affymetrix Inc
10.12 Subtle Pharmaceuticals Pvt. Ltd.
10.13 Precision Therapeutics
List of Tables
Table 1 Global Non-Invasive Cancer Diagnostics Market Outlook, By Region (2020-2028) ($MN)
Table 2 Global Non-Invasive Cancer Diagnostics Market Outlook, By Therapeutics (2020-2028) ($MN)
Table 3 Global Non-Invasive Cancer Diagnostics Market Outlook, By Lung Cancer (2020-2028) ($MN)
Table 4 Global Non-Invasive Cancer Diagnostics Market Outlook, By Breast Cancer (2020-2028) ($MN)
Table 5 Global Non-Invasive Cancer Diagnostics Market Outlook, By Solid Tumors (2020-2028) ($MN)
Table 6 Global Non-Invasive Cancer Diagnostics Market Outlook, By Blood Cancer (2020-2028) ($MN)
Table 7 Global Non-Invasive Cancer Diagnostics Market Outlook, By Other Therapeutics (2020-2028) ($MN)
Table 8 Global Non-Invasive Cancer Diagnostics Market Outlook, By Technology (2020-2028) ($MN)
Table 9 Global Non-Invasive Cancer Diagnostics Market Outlook, By Clinical Chemistry (2020-2028) ($MN)
Table 10 Global Non-Invasive Cancer Diagnostics Market Outlook, By Spectroscopy (2020-2028) ($MN)
Table 11 Global Non-Invasive Cancer Diagnostics Market Outlook, By Immunoassay (2020-2028) ($MN)
Table 12 Global Non-Invasive Cancer Diagnostics Market Outlook, By Molecular Diagnostics (2020-2028) ($MN)
Table 13 Global Non-Invasive Cancer Diagnostics Market Outlook, By Other Technologies (2020-2028) ($MN)
Table 14 Global Non-Invasive Cancer Diagnostics Market Outlook, By End user (2020-2028) ($MN)
Table 15 Global Non-Invasive Cancer Diagnostics Market Outlook, By Hospitals & Clinics (2020-2028) ($MN)
Table 16 Global Non-Invasive Cancer Diagnostics Market Outlook, By Ambulatory Care (2020-2028) ($MN)
Table 17 Global Non-Invasive Cancer Diagnostics Market Outlook, By Other End Users (2020-2028) ($MN)
Table 18 North America Non-Invasive Cancer Diagnostics Market Outlook, By Country (2020-2028) ($MN)
Table 19 North America Non-Invasive Cancer Diagnostics Market Outlook, By Therapeutics (2020-2028) ($MN)
Table 20 North America Non-Invasive Cancer Diagnostics Market Outlook, By Lung Cancer (2020-2028) ($MN)
Table 21 North America Non-Invasive Cancer Diagnostics Market Outlook, By Breast Cancer (2020-2028) ($MN)
Table 22 North America Non-Invasive Cancer Diagnostics Market Outlook, By Solid Tumors (2020-2028) ($MN)
Table 23 North America Non-Invasive Cancer Diagnostics Market Outlook, By Blood Cancer (2020-2028) ($MN)
Table 24 North America Non-Invasive Cancer Diagnostics Market Outlook, By Other Therapeutics (2020-2028) ($MN)
Table 25 North America Non-Invasive Cancer Diagnostics Market Outlook, By Technology (2020-2028) ($MN)
Table 26 North America Non-Invasive Cancer Diagnostics Market Outlook, By Clinical Chemistry (2020-2028) ($MN)
Table 27 North America Non-Invasive Cancer Diagnostics Market Outlook, By Spectroscopy (2020-2028) ($MN)
Table 28 North America Non-Invasive Cancer Diagnostics Market Outlook, By Immunoassay (2020-2028) ($MN)
Table 29 North America Non-Invasive Cancer Diagnostics Market Outlook, By Molecular Diagnostics (2020-2028) ($MN)
Table 30 North America Non-Invasive Cancer Diagnostics Market Outlook, By Other Technologies (2020-2028) ($MN)
Table 31 North America Non-Invasive Cancer Diagnostics Market Outlook, By End user (2020-2028) ($MN)
Table 32 North America Non-Invasive Cancer Diagnostics Market Outlook, By Hospitals & Clinics (2020-2028) ($MN)
Table 33 North America Non-Invasive Cancer Diagnostics Market Outlook, By Ambulatory Care (2020-2028) ($MN)
Table 34 North America Non-Invasive Cancer Diagnostics Market Outlook, By Other End Users (2020-2028) ($MN)
Table 35 Europe Non-Invasive Cancer Diagnostics Market Outlook, By Country (2020-2028) ($MN)
Table 36 Europe Non-Invasive Cancer Diagnostics Market Outlook, By Therapeutics (2020-2028) ($MN)
Table 37 Europe Non-Invasive Cancer Diagnostics Market Outlook, By Lung Cancer (2020-2028) ($MN)
Table 38 Europe Non-Invasive Cancer Diagnostics Market Outlook, By Breast Cancer (2020-2028) ($MN)
Table 39 Europe Non-Invasive Cancer Diagnostics Market Outlook, By Solid Tumors (2020-2028) ($MN)
Table 40 Europe Non-Invasive Cancer Diagnostics Market Outlook, By Blood Cancer (2020-2028) ($MN)
Table 41 Europe Non-Invasive Cancer Diagnostics Market Outlook, By Other Therapeutics (2020-2028) ($MN)
Table 42 Europe Non-Invasive Cancer Diagnostics Market Outlook, By Technology (2020-2028) ($MN)
Table 43 Europe Non-Invasive Cancer Diagnostics Market Outlook, By Clinical Chemistry (2020-2028) ($MN)
Table 44 Europe Non-Invasive Cancer Diagnostics Market Outlook, By Spectroscopy (2020-2028) ($MN)
Table 45 Europe Non-Invasive Cancer Diagnostics Market Outlook, By Immunoassay (2020-2028) ($MN)
Table 46 Europe Non-Invasive Cancer Diagnostics Market Outlook, By Molecular Diagnostics (2020-2028) ($MN)
Table 47 Europe Non-Invasive Cancer Diagnostics Market Outlook, By Other Technologies (2020-2028) ($MN)
Table 48 Europe Non-Invasive Cancer Diagnostics Market Outlook, By End user (2020-2028) ($MN)
Table 49 Europe Non-Invasive Cancer Diagnostics Market Outlook, By Hospitals & Clinics (2020-2028) ($MN)
Table 50 Europe Non-Invasive Cancer Diagnostics Market Outlook, By Ambulatory Care (2020-2028) ($MN)
Table 51 Europe Non-Invasive Cancer Diagnostics Market Outlook, By Other End Users (2020-2028) ($MN)
Table 52 Asia Pacific Non-Invasive Cancer Diagnostics Market Outlook, By Country (2020-2028) ($MN)
Table 53 Asia Pacific Non-Invasive Cancer Diagnostics Market Outlook, By Therapeutics (2020-2028) ($MN)
Table 54 Asia Pacific Non-Invasive Cancer Diagnostics Market Outlook, By Lung Cancer (2020-2028) ($MN)
Table 55 Asia Pacific Non-Invasive Cancer Diagnostics Market Outlook, By Breast Cancer (2020-2028) ($MN)
Table 56 Asia Pacific Non-Invasive Cancer Diagnostics Market Outlook, By Solid Tumors (2020-2028) ($MN)
Table 57 Asia Pacific Non-Invasive Cancer Diagnostics Market Outlook, By Blood Cancer (2020-2028) ($MN)
Table 58 Asia Pacific Non-Invasive Cancer Diagnostics Market Outlook, By Other Therapeutics (2020-2028) ($MN)
Table 59 Asia Pacific Non-Invasive Cancer Diagnostics Market Outlook, By Technology (2020-2028) ($MN)
Table 60 Asia Pacific Non-Invasive Cancer Diagnostics Market Outlook, By Clinical Chemistry (2020-2028) ($MN)
Table 61 Asia Pacific Non-Invasive Cancer Diagnostics Market Outlook, By Spectroscopy (2020-2028) ($MN)
Table 62 Asia Pacific Non-Invasive Cancer Diagnostics Market Outlook, By Immunoassay (2020-2028) ($MN)
Table 63 Asia Pacific Non-Invasive Cancer Diagnostics Market Outlook, By Molecular Diagnostics (2020-2028) ($MN)
Table 64 Asia Pacific Non-Invasive Cancer Diagnostics Market Outlook, By Other Technologies (2020-2028) ($MN)
Table 65 Asia Pacific Non-Invasive Cancer Diagnostics Market Outlook, By End user (2020-2028) ($MN)
Table 66 Asia Pacific Non-Invasive Cancer Diagnostics Market Outlook, By Hospitals & Clinics (2020-2028) ($MN)
Table 67 Asia Pacific Non-Invasive Cancer Diagnostics Market Outlook, By Ambulatory Care (2020-2028) ($MN)
Table 68 Asia Pacific Non-Invasive Cancer Diagnostics Market Outlook, By Other End Users (2020-2028) ($MN)
Table 69 South America Non-Invasive Cancer Diagnostics Market Outlook, By Country (2020-2028) ($MN)
Table 70 South America Non-Invasive Cancer Diagnostics Market Outlook, By Therapeutics (2020-2028) ($MN)
Table 71 South America Non-Invasive Cancer Diagnostics Market Outlook, By Lung Cancer (2020-2028) ($MN)
Table 72 South America Non-Invasive Cancer Diagnostics Market Outlook, By Breast Cancer (2020-2028) ($MN)
Table 73 South America Non-Invasive Cancer Diagnostics Market Outlook, By Solid Tumors (2020-2028) ($MN)
Table 74 South America Non-Invasive Cancer Diagnostics Market Outlook, By Blood Cancer (2020-2028) ($MN)
Table 75 South America Non-Invasive Cancer Diagnostics Market Outlook, By Other Therapeutics (2020-2028) ($MN)
Table 76 South America Non-Invasive Cancer Diagnostics Market Outlook, By Technology (2020-2028) ($MN)
Table 77 South America Non-Invasive Cancer Diagnostics Market Outlook, By Clinical Chemistry (2020-2028) ($MN)
Table 78 South America Non-Invasive Cancer Diagnostics Market Outlook, By Spectroscopy (2020-2028) ($MN)
Table 79 South America Non-Invasive Cancer Diagnostics Market Outlook, By Immunoassay (2020-2028) ($MN)
Table 80 South America Non-Invasive Cancer Diagnostics Market Outlook, By Molecular Diagnostics (2020-2028) ($MN)
Table 81 South America Non-Invasive Cancer Diagnostics Market Outlook, By Other Technologies (2020-2028) ($MN)
Table 82 South America Non-Invasive Cancer Diagnostics Market Outlook, By End user (2020-2028) ($MN)
Table 83 South America Non-Invasive Cancer Diagnostics Market Outlook, By Hospitals & Clinics (2020-2028) ($MN)
Table 84 South America Non-Invasive Cancer Diagnostics Market Outlook, By Ambulatory Care (2020-2028) ($MN)
Table 85 South America Non-Invasive Cancer Diagnostics Market Outlook, By Other End Users (2020-2028) ($MN)
Table 86 Middle East & Africa Non-Invasive Cancer Diagnostics Market Outlook, By Country (2020-2028) ($MN)
Table 87 Middle East & Africa Non-Invasive Cancer Diagnostics Market Outlook, By Therapeutics (2020-2028) ($MN)
Table 88 Middle East & Africa Non-Invasive Cancer Diagnostics Market Outlook, By Lung Cancer (2020-2028) ($MN)
Table 89 Middle East & Africa Non-Invasive Cancer Diagnostics Market Outlook, By Breast Cancer (2020-2028) ($MN)
Table 90 Middle East & Africa Non-Invasive Cancer Diagnostics Market Outlook, By Solid Tumors (2020-2028) ($MN)
Table 91 Middle East & Africa Non-Invasive Cancer Diagnostics Market Outlook, By Blood Cancer (2020-2028) ($MN)
Table 92 Middle East & Africa Non-Invasive Cancer Diagnostics Market Outlook, By Other Therapeutics (2020-2028) ($MN)
Table 93 Middle East & Africa Non-Invasive Cancer Diagnostics Market Outlook, By Technology (2020-2028) ($MN)
Table 94 Middle East & Africa Non-Invasive Cancer Diagnostics Market Outlook, By Clinical Chemistry (2020-2028) ($MN)
Table 95 Middle East & Africa Non-Invasive Cancer Diagnostics Market Outlook, By Spectroscopy (2020-2028) ($MN)
Table 96 Middle East & Africa Non-Invasive Cancer Diagnostics Market Outlook, By Immunoassay (2020-2028) ($MN)
Table 97 Middle East & Africa Non-Invasive Cancer Diagnostics Market Outlook, By Molecular Diagnostics (2020-2028) ($MN)
Table 98 Middle East & Africa Non-Invasive Cancer Diagnostics Market Outlook, By Other Technologies (2020-2028) ($MN)
Table 99 Middle East & Africa Non-Invasive Cancer Diagnostics Market Outlook, By End user (2020-2028) ($MN)
Table 100 Middle East & Africa Non-Invasive Cancer Diagnostics Market Outlook, By Hospitals & Clinics (2020-2028) ($MN)
Table 101 Middle East & Africa Non-Invasive Cancer Diagnostics Market Outlook, By Ambulatory Care (2020-2028) ($MN)
Table 102 Middle East & Africa Non-Invasive Cancer Diagnostics Market Outlook, By Other End Users (2020-2028) ($MN)
| ※参考情報 非侵襲的がん診断は、体に大きな負担をかけずにがんを検出するための手法や技術を指します。従来のがん診断方法は、手術や針生検などを用いて組織を直接採取することが多く、これには身体的なリスクや痛みが伴う場合があります。しかし、非侵襲的なアプローチでは、体に直接的な侵入を行わず、血液、尿、唾液などの体液を利用してがんを診断します。 非侵襲的がん診断の代表的な種類の一つは、血液検査です。これはがん細胞が血液中に放出するバイオマーカー（特異的なタンパク質やDNA断片など）を検出することで行われます。例としては、がん性抗原に関連する腫瘍マーカーの測定や、循環腫瘍DNA（ctDNA）を用いた検査が挙げられます。ctDNAは、腫瘍細胞から放出される微量のDNAであり、それを解析することでがんの有無や進行度を評価することができます。 もう一つの重要な非侵襲的がん診断の手法は、画像診断です。ここにはCT（コンピュータ断層撮影）、MRI（磁気共鳴画像法）、超音波検査などが含まれます。これらの技術は、体内の構造を可視化し、腫瘍の存在やその大きさ、形状を把握することができます。特に、MRIは軟部組織の描写が得意で、脳や肝臓などのがんの診断に効果的です。 非侵襲的がん診断の用途は多岐にわたりますが、その主な目的は早期発見です。がんは早期に発見されるほど治療の選択肢が増え、予後が良好になる可能性があります。したがって、高リスク群に対するスクリーニングや、治療後の再発モニタリングにも多く用いられています。定期的な血液検査により、がんの再発を早期に発見することが可能です。 関連技術としては、合成生物学やマイクロ流体技術も挙げられます。合成生物学は、バイオマーカーの集合を更に改善し、より高精度な診断法の開発を促進します。一方、マイクロ流体技術は、非常に少量の体液から多くの情報を得ることを可能にし、最小限の量で高度な分析を行うことを実現します。これにより、診断スピードが向上し、さらに患者の負担が軽減されます。 非侵襲的がん診断は、患者に優しいだけでなく、医療システム全体においても効率を向上させる可能性があります。例えば、侵襲的な手法に比べて入院の必要が少なく、診断に伴う時間やコストも削減できます。 今後の展望としては、人工知能（AI）や機械学習を活用したデータ解析技術の進展が期待されています。これにより、より迅速かつ正確な診断が行われ、個別化医療の実現に寄与することができるでしょう。AIは、大量のデータを解析し、病歴や遺伝情報と組み合わせることで、リスク評価を行い、早期診断の精度を向上させる可能性があります。 非侵襲的がん診断は、今後ますます重要な役割を果たすと考えられています。新たな技術の開発や改善により、がんに対する理解と治療法の向上が期待され、患者の生存率向上と生活の質の向上に寄与することができるでしょう。診断精度の向上は、がん治療における革新にもつながり、今後の医療において革新的な進展をもたらす可能性を秘めています。 |
